WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. The deal includes facilities in ...

(Bloomberg) -- WuXi AppTec Co. posted better-than-expected third-quarter revenue despite concerns over a US bill seeking to ...

China's WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum. The contract development and ...

Chinese electric-car maker Li Auto and pharmaceutical company WuXi Apptec will join the Hang Seng Index as new constituents next month, according to the latest quarterly review by Hong Kong’s ...

WuXi AppTec Co, Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene ...

The Biotechnology Innovation Organization (BIO) has said it is parting company with Wuxi AppTec, while voicing support for US legislation that would block Chinese biotechs from federal funding and ...

WuXi AppTec says it voluntarily left a high-profile biotechnology lobbying group as U.S. legislative efforts were “maligning” its membership in the Washington-based association. A letter sent ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from ...

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than ...

Contract research organisation (CRO) NAMSA has acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities. The deal ...

Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...

Founded in 2001 as WuXi PharmaTech, the company rebranded to its current name after acquiring the U.S.-based AppTec Laboratory Services in 2008. Long Wei—Feature China/Future Publishing/Getty Images ...